Flying in the age of coronavirus comes packed with uncertainty about the health status of fellow travelers. Now, Florida's Tampa International Airport is running a pilot program that offers on-the-spot COVID-19 tests for travelers.

With more than 120 people participating in the optional testing per day, Joe Lopano, Tampa International Airport CEO, said the program is showing promising results.

"We've had some customers who have tested positive and Baycare, the healthcare professionals, have a discussion with that passenger and tell them that they should not continue on their way and passengers have accepted it," Lopano told Cheddar.

The airport offers two tests, the $125 PCR nasal swab, which usually takes 3 to 4 days to yield results, and the $50 rapid Antigen test. The cost of both tests, Lopano said, can be covered by insurance companies if travelers provide a receipt from the airport.

Testing at the airport, according to Lopano, will not have much impact on overall travel time. In fact, those not checking a bag only need to account for an additional 30 minutes as a cushion, he added. 

"It's immediate testing. Sometimes you have to wait in a short line. You'll get your results in 15 minutes, so it really is not a very time-consuming function and it's very convenient," Lopano said.

While other airports have implemented testing for specific destinations, Lopano said Tampa is the first to offer widespread testing for passengers on all flights arriving and departing. The pilot program is likely to continue running through the holiday season as the number of participants and customer satisfaction is assessed.

For Lopano, offering a testing site at the airport is not only maintaining passenger safety but can also help revitalize a struggling travel industry that is fighting to get customers off the ground.

"It's a high priority because we need to do whatever we can to create confidence in the travel experience and now that widespread testing is available, the technology is available, what better way to do that than right at the airport," he said.

Share:
More In Business
Regeneron Joins Battle Against COVID-19, Releases Stats on New COVID Treatment
The world hit a grim milestone on Monday, with COVID-19 cases surpassing a quarter of a billion worldwide. As cases increase, the fight to beat the virus continues as well, with a number of medical breakthroughs coming out over the last few months in the form of pills from Pfizer and Merck. Regeneron is now the latest company to join the fight, recently releasing new data on a covid antibody cocktail. Professor Peter Pitts, former FDA Associate Commissioner and the founder of the Center for Medicine in the Public Interest breaks down the differences between the 3 treatments and why vaccines are still among the fire line of defense.
Peloton Stock Continues Steep Drop as It Loses More Than $10B in Value
Doug Astrop, managing partner at Exponential Investment Partners, joined Cheddar to discuss Peloton's precipitous price drop, and whether the company can recover as the at-home workout trend tapers off. "They've lowered the prices on their equipment to try to attract a bigger audience because ultimately they're sort of headed to this Apple ecosystem model where they can monetize a loyal customer base," he said. Astrop noted that he believes there is a reality where the in-person gym experience and Peloton's at-home programs can co-exist.
Markets Look to Continue Record Run
Bill Stone, Chief Investment Officer at Glenview Trust Company, joined Wake Up With Cheddar to break down markets headlines ahead of the start of the trading week.
Load More